|
|
Article: Research and Markets: Metabolic Syndrome: Pipeline Analysis and U.S. Market Forecast.
- Article from:
- Business Wire
- Article date:
- February 2, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c12511) has announced the addition of Metabolic Syndrome: Pipeline Analysis and U.S. Market Forecast to their offering
This is a thorough evaluation of marketed therapies and drugs in development for obesity, dyslipidemia, type 2 diabetes, and hypertension.
Metabolic Syndrome is a cluster of risk factors for atherosclerotic disease and type 2 diabetes mellitus comprising obesity, insulin resistance, hypertension, and dyslipidemia. The eligible treatment population in the U.S. for these four conditions is currently 40 million patients and will nearly double over the next ...